Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Amgen’s copy of AbbVie arthritis drug Humira

The U.S. Food and Drug Administration approved Amgen’s biosimilar version of AbbVie’s top-selling arthritis drug Humira.

Read More »

Endo CEO steps down; successor named

Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.

Read More »

Six in the running to be next World Health Organization leader

Six international health experts, including four from Europe, are to compete to become the next director general of the World Health Organization (WHO) after its current leader Margaret Chan ends her tenure in June 2017.

Read More »

UPS launches U.S. drone test flights for urgent medical deliveries

United Parcel Service Inc. said it began testing the use of drones for emergency deliveries of medical supplies with a flight in rural Massachusetts, which the company hopes will eventually lead to federal approval of drones as a regular delivery option.

Read More »

Novartis’ Zykadia gets positive results

Novartis’ Zykadia drug performed well against a rare form of lung cancer, citing a study the Swiss company hopes will help it win expanded regulatory approval.

Read More »

Saga Continues for Sarepta as FDA Head Calls for Retraction of ‘Misleading’ 2013 Study

The months-long drama involving Sarepta Therapeutics’ eteplilrsen for Duchenne Muscular Dystrophy (DMD) and the U.S. Food and Drug Administration is not over, despite the drug’s accelerated approval.

Read More »

H. Lundbeck’s Phase III Data Crushes Hope for Alzheimer’s Once Again

Danish company H. Lundbeck A/S announced its experimental Alzheimer’s treatment idalopirdine failed in a late-stage trial.

Read More »

U.S. states sue opioid-maker Indivior, alleging anticompetitive practices

Thirty-five U.S. states and the District of Columbia filed a lawsuit against opioid drug maker Indivior alleging it tried to keep generic versions of a drug off the market.

Read More »

Hard to swallow: emerging markets get tougher for drugmakers

Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building.

Read More »

UnitedHealth trims drug coverage

UnitedHealth Group, the largest U.S. health insurer, will stop covering several brand-name drugs as of 2017, including Sanofi’s long-acting insulin Lantus.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom